samedan logo
 
 
spacer
home > pmps > summer 2021 > supporting patient safety in acute care settings
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Supporting Patient Safety in Acute Care Settings

Acute care operates on the frontline of medicine, be it in response to traumatic injury in an accident or to stroke, heart attack, diabetic coma, or other emergency posing an imminent threat to a patient’s life. As such, it encompasses all emergency medical services – from first professional response at the scene of an accident or incident, on board of rescue ambulances or medevac helicopters, in the hospital emergency and operating room, surgical ward, and treatment in the intensive care unit.

This field, no doubt, entails massive psychological stress and time pressure for the professionals – physicians, nurses, and paramedics – who work in it. Decisions and actions typically have to be taken in a matter of minutes or even seconds, while errors must be avoided at all costs. Accidentally administering the wrong medication due to time pressure can seriously harm and even jeopardise the patient’s life.

Especially in these high-stress scenarios, medicines that are readily and reliably identifiable by their marking labels can help to prevent medication errors. Ensuring that the products are originals rather than fakes and have not been opened before their intended use, refilled/repackaged, diluted, exchanged, or tampered with in other ways, is equally important. Advanced analogue and digital security label solutions including first-opening indication, tamper-evident and anti-counterfeiting features provide such assurance. Last but not least, a transparent and reliable hospital supply chain and medication management using modern digital technology ensure that the right medicine is available at the right time especially in emergency situations.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Stefan Wiedemann is Senior Director Strategic Marketing and Business Development at Schreiner MediPharm, a business unit of Schreiner Group based in Oberschleissheim near Munich, Germany. Stefan is in charge of strategy and business development. At Schreiner MediPharm, he has been focusing strongly on the development of packaging-based business in the area of patient safety, anti-counterfeiting, drug protection, compliance monitoring, and connectivity. Prior to joining Schreiner MediPharm in 2006, Stefan held positions as Head of Market and Strategy at Paper Technology Specialists, as well as Management Consultant at DGM (Roland Berger/Deutsche Bank). He holds a degree in Business Administration from the University of Bayreuth, Germany.

Dr Andreas Hofenauer is Senior Manager Innovation and Strategic Partnerships Healthcare at Schreiner MediPharm. Andreas is in charge of identifying new product solutions that are optimally tailored to specific market and customer requirements. Prior to joining Schreiner MediPharm in 2013, Andreas worked as Department Head in the paper industry in the field of innovation for several years. He graduated and received the Doctoral degree in natural sciences at the Technical University of Munich, Germany.
spacer
Stefan Wiedemann
spacer
spacer
spacer
Dr Andreas Hofenauer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults

 BYANNLI® (6-monthly paliperidone palmitate; PP6M) is the first long-acting injectable schizophrenia treatment to be approved with a twice-yearly dosing regimen[1] . The approval is based on results from the Route 6 Study, which showed that 92.5 percent of patients treated with PP6M were relapse-free at the end of the 12-month double-blind phase1.  
More info >>

White Papers

Inhaler Adherence: Exploring Key Factors

Aptar Pharma

Aptar Pharma recently hosted an expert panel roundtable on “Inhaler Adherence”. This international scientific forum was held in Paris, France on November 29th 2013. The roundtable was organized to explore and exchange views on the issues which may influence inhaler adherence/ compliance with a particular focus on asthma and C.O.P.D. therapies and their corresponding inhaler devices (MDIs, DPIs).
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement